Boston Scientific Lawsuit Updates: Securities Fraud, MDL, and Recalls

Boston Scientific Corporation is currently defending a securities fraud class action lawsuit filed in March 2026 over alleged misstatements about its Farapulse electrophysiology business, along with a newly consolidated multidistrict litigation over its spinal cord stimulator devices. The company is also managing fallout from two Class I FDA recalls — one covering roughly 156,000 Accolade pacemakers, the other covering Watchman implant access systems — and has previously paid hundreds of millions of dollars to resolve transvaginal mesh claims, a prior securities case tied to its LOTUS Edge heart valve, and False Claims Act allegations inherited from its Guidant acquisition.

The 2026 Securities Fraud Class Action

Troike v. Boston Scientific Corporation et al. was filed on March 5, 2026, in the United States District Court for the District of Massachusetts and assigned to District Judge Julia E. Kobick.¹ The proposed class period runs from July 23, 2025, through February 3, 2026. Named defendants include the company, CEO and Chairman Michael F. Mahoney, CFO Jonathan R. Monson, Chief Medical Officer Kenneth M. Stein, EVP of Cardiology Joseph M. Fitzgerald, and Global President of Electrophysiology Nicholas Spadea-Anello.²

What Investors Allege

The complaint claims Boston Scientific executives overstated the health of the electrophysiology segment, particularly its Farapulse pulsed field ablation platform, while downplaying signs of decelerating growth and rising competition. Management is alleged to have projected 15% long-term market growth and predicted PFA penetration would climb from 50% to 80% by 2028.³

Plaintiffs point to a sharp deceleration hidden in plain sight: EP segment revenue growth fell from 94% year-over-year in Q2 2025 to 63% in Q3 2025, yet management framed the Q3 result as evidence of “continued share gains.”³ Executives are alleged to have described competitors as “late entrants with inferior technology” and told investors as late as December 2, 2025, that they had a “very good understanding of what competition we will face and in what time frame.”² At the company’s September 30, 2025, Analyst/Investor Day, Spadea-Anello told investors the company’s vision was “not just to be a leader in pulse field ablation, but to be a leader in overall electrophysiology,” and described Boston Scientific as “insulating” itself against competitive threats.⁴

The February 4, 2026 Disclosure and Stock Drop

On February 4, 2026, Boston Scientific released fourth-quarter and full-year 2025 results with disappointing U.S. EP sales and 2026 guidance well below analyst expectations. Mahoney acknowledged the company had “lost some share” to new market entrants and said actual EP market growth was closer to 18% to 20%.² The EP segment missed consensus estimates by roughly $33 million.⁵ Shares fell from $91.62 to $75.50 that day, a decline of about 17.6%.⁶

Where the Case Stands

The lead-plaintiff application deadline was May 4, 2026. As of early June 2026, the case remained in early procedural stages with motions to appoint counsel filed. No class had been certified.¹

Spinal Cord Stimulator MDL

On June 5, 2026, the Judicial Panel on Multidistrict Litigation created MDL No. 3181, In re: Boston Scientific Corporation Spinal Cord Stimulator Products Liability Litigation, centralizing claims in the Central District of California before Judge Josephine L. Staton. The MDL initially covered 23 cases, with 12 lawsuits transferred at the time of creation.⁷

The lawsuits target Boston Scientific’s WaveWriter, Precision, and Precision Spectra stimulators. Plaintiffs report worsening pain, electrical shocks, burning sensations, lead migration, neurological damage, loss of bowel or bladder control, and the need for surgical removal. Their legal theories allege that Boston Scientific obtained FDA premarket approval by relying on competitors’ clinical data, used the PMA supplement process to introduce modifications without adequate scrutiny, failed to warn of known risks, and let sales representatives participate in surgical procedures and device programming — conduct they characterize as unauthorized practice of medicine.⁷

The panel declined to create an industrywide MDL that would have swept in Abbott Laboratories, Nevro, and Medtronic, finding those manufacturers involved different device designs, separate regulatory histories, and distinct conduct.⁷

Accolade Pacemaker Recall

Boston Scientific’s Accolade family of pacemakers and cardiac resynchronization therapy devices — including the Accolade, Proponent, Essentio, Altrua 2, Visionist, and Valitude models — is the subject of a Class I FDA recall originally issued February 21, 2025. A manufacturing defect involving the battery cathode causes high battery impedance, which can force devices into an irreversible “Safety Mode” that strips away programmed therapy and limits pacing capability.⁸

The root cause is an unanticipated concentration of lithium salts during battery assembly that creates an electrolyte shortage. High-power telemetry operations drop voltage below a critical threshold and trigger resets; three resets within 48 hours put the device into Safety Mode. A published clinical report found a 52% rate of major complications among patients whose devices entered Safety Mode.⁹

As of March 18, 2026, Boston Scientific had reported four deaths and 2,557 serious injuries associated with the defect to the FDA.⁸ The defect potentially affects approximately 156,000 devices worldwide.¹⁰ Boston Scientific issued a mandatory software update (Brady SMR6) intended to fix the behaviors introduced by earlier firmware.

No class action specific to the Accolade defect had been publicly announced as of mid-2026, though plaintiffs’ firms were actively investigating claims. Reports indicated Boston Scientific was offering $2,500 to affected patients to cover costs related to device replacement surgery.¹⁰

Watchman Access System Recall

The Watchman left atrial appendage closure device became the subject of a Class I FDA recall in August 2025 tied to a risk of air embolism during implantation. The FDA found that patients under conscious or deep sedation, rather than general anesthesia with positive-pressure ventilation, were three times more likely to experience complications such as stroke, organ failure, abnormal heart rhythm, and hemodynamic collapse. Boston Scientific reported 120 serious injuries and 17 deaths associated with the issue as of the recall date. The corrective action involved updated instructions for use and physician training for the Watchman TruSeal, FXD Curve, and TruSteer access systems. Patients already living with an implanted device were not affected — the risk was limited to the implant procedure itself.¹¹ No MDL or consolidated litigation over the Watchman device had been announced as of mid-2026.

Transvaginal Mesh Litigation

The largest volume of litigation in Boston Scientific’s history involves transvaginal mesh implants used to treat pelvic organ prolapse and stress urinary incontinence. More than 70,000 cases were consolidated in MDL No. 2326 in the Southern District of West Virginia before U.S. District Judge Joseph Goodwin.¹² The MDL was terminated in February 2021.¹³

Notable jury verdicts included:

September 2014: $73 million to Martha Salazar over the Obtryx sling, including $50 million in punitive damages, later reduced to $34.5 million.¹⁴
November 2014: $26.7 million to four women implanted with Pinnacle mesh and $18.5 million to four women implanted with Obtryx mesh.¹⁴
May 2015: A Delaware jury awarded $100 million ($25 million compensatory, $75 million punitive) after finding the Pinnacle and Advantage Fit products were defectively designed and that the company committed fraud by concealing problems. A judge later reduced the award to $10 million.¹⁴
October 2016: A West Virginia judge upheld a $14.3 million award for three plaintiffs involving Obtryx mesh.¹⁴

The company also won defense verdicts in some trials, including Albright v. Boston Scientific and Cardenas v. Boston Scientific, both decided in 2014 in Massachusetts, where juries found no design or warning defects in the Pinnacle and Obtryx products respectively.¹⁵

In April 2015, Boston Scientific agreed to pay roughly $119 million to resolve about 3,000 cases. By October 2015, the company disclosed in an SEC filing that it had settled approximately 6,000 mesh lawsuits for a total of $457 million through the third quarter of that year, with roughly 20,000 cases still outstanding at that point.¹⁴

The LOTUS Edge Securities Settlement

An earlier securities case, In re Boston Scientific Corporation Securities Litigation (Case No. 1:20-cv-12225-ADB), was brought in the District of Massachusetts over the company’s LOTUS Edge transcatheter aortic valve replacement device. Investors alleged executives touted the device’s “ease of use” and successful launch while the delivery system was seriously flawed. The truth came out on November 17, 2020, when Boston Scientific recalled the LOTUS Edge and terminated the product line. The class period ran from September 16 to November 16, 2020.¹⁶

The case settled for $38.5 million in cash. The court approved the settlement on April 23, 2024, with an initial distribution to class members in April 2025 and a second in February 2026.¹⁷ Plaintiffs’ counsel received up to 20% of the fund in attorneys’ fees, plus approved expenses of up to $700,000.¹⁸ Reuters reported in January 2022 that the SEC had closed a related probe into the LOTUS Edge shutdown without enforcement action.¹⁹

False Claims Act History

Two settlements grew out of Boston Scientific’s 2006 acquisition of Guidant Corporation. In 2011, Guidant LLC paid $9.25 million to resolve allegations that it inflated the cost of replacement pacemakers and defibrillators by failing to grant mandatory warranty credits and rebates to hospitals, passing inflated costs on to the Department of Veterans Affairs, the Department of Defense, and Medicare. Whistleblower Robert A. Fry received over $2.3 million.²⁰

In 2013, Boston Scientific and Guidant subsidiaries paid $30 million to settle claims that Guidant knowingly sold defective Prizm, Renewal 1, and Renewal 2 cardiac defibrillators to healthcare providers, which were implanted in Medicare patients. Whistleblower James Allen, himself a patient with one of the defective devices, received $2.25 million. Guidant had previously pleaded guilty to related criminal charges in February 2010.²¹

A separate qui tam case, United States ex rel. Higgins v. Boston Scientific Corp., alleged that Boston Scientific concealed design defects in its Cognis and Teligen defibrillators to obtain FDA approval. The government declined to intervene, and in August 2021 a federal court in Minnesota granted summary judgment to Boston Scientific, finding the whistleblower failed to establish that any alleged false statement to the FDA was material to the approval decision.²²

1
Docket Alarm. Troike v Boston Scientific Corporation et al
2
Levi & Korsinsky. Boston Scientific Corporation Class Action Lawsuit
3
PR Newswire. BSX Investor Alert
4
Levi & Korsinsky. BSX Complaint
5
MD+DI Online. Boston Scientific’s Electrophysiology Segment Earnings Confirm Investor Fears
6
The Gross Law Firm via PR Newswire. Class Action Filed Against Boston Scientific Corporation
7
JPML. MDL-3181 Transfer Order
8
FDA. Pacemaker Correction: Accolade Pacemakers and CRT-Ps
9
Boston Scientific. Accolade SafetyMode Physician Letter
10
Seeger Weiss. Accolade Pacemaker Lawsuit
11
FDA. Vascular Access Systems Correction: Watchman Access
12
Ashcraft & Gerel. Boston Scientific to Pay $100M in Transvaginal Mesh
13
U.S. District Court, Southern District of West Virginia. MDL 2326
14
ClassAction.com. Transvaginal Mesh Settlement
15
Shook Hardy & Bacon. Pelvic Mesh Trials
16
Bernstein Litowitz Berger & Grossmann. Boston Scientific
17
Boston Scientific Securities Litigation. In re Boston Scientific Corporation Securities Litigation
18
Boston Scientific Securities Litigation. Securities Litigation FAQ
19
Reuters. SEC Closes Probe Into Boston Scientific’s Heart Device Shutdown
20
U.S. Department of Justice. Boston Scientific Subsidiary Guidant Pays $9.25 Million
21
Waters Kraus & Paul. Boston Scientific Settles False Claims Act Suit
22
U.S. District Court, District of Minnesota. United States v. Boston Scientific Corp.